Compare AstraZeneca plc (AZN) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Schwab US Dividend Equity ETF — how do they compare? AstraZeneca plc trades at $157.91 (market cap $248.14B), while Schwab US Dividend Equity ETF trades at $34.17. The key difference: AstraZeneca plc pays a 2.01% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SCHD | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $34.27 |
52-Week Low | $147.06 | $26.44 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
SCHD trades at $34.11, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is a core holding for dividend investors, highlighted by a recent $0.25 dividend declaration for June 2026. Media coverage emphasizes its role in retirement income strategies, though some articles note performance gaps versus peers like VYM.
Outlook remains stable for income-focused investors, with SCHD offering reliable dividends amid market rotations. Risks include interest rate sensitivity and tax inefficiencies in taxable accounts. Institutional interest persists, as seen in Barry Investment Advisors' 29.9% stake increase in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
